Consensus nomenclature for CD8(+) T cell phenotypes in cancer.
Document Type
Article
Publication Date
4-1-2015
JAX Location
Reprint Collection
JAX Source
Oncoimmunology 2015 Apr; 4(4):e998538
Volume
4
Issue
4
First Page
998538
Last Page
998538
ISSN
2162-4011
PMID
26137416
Abstract
Whereas preclinical investigations and clinical studies have established that CD8(+) T cells can profoundly affect cancer progression, the underlying mechanisms are still elusive. Challenging the prevalent view that the beneficial effect of CD8(+) T cells in cancer is solely attributable to their cytotoxic activity, several reports have indicated that the ability of CD8(+) T cells to promote tumor regression is dependent on their cytokine secretion profile and their ability to self-renew. Evidence has also shown that the tumor microenvironment can disarm CD8(+) T cell immunity, leading to the emergence of dysfunctional CD8(+) T cells. The existence of different types of CD8(+) T cells in cancer calls for a more precise definition of the CD8(+) T cell immune phenotypes in cancer and the abandonment of the generic terms "pro-tumor" and "antitumor." Based on recent studies investigating the functions of CD8(+) T cells in cancer, we here propose some guidelines to precisely define the functional states of CD8(+) T cells in cancer. Oncoimmunology 2015 Apr; 4(4):e998538
Recommended Citation
Apetoh L,
Smyth M,
Drake C,
Abastado J,
Apte R,
Ayyoub M,
Blay J,
Bonneville M,
Butterfield L,
Caignard A,
Castelli C,
Cavallo F,
Celis E,
Chen L,
Colombo M,
Comin-Anduix B,
Coukos G,
Dhodapkar M,
Dranoff G,
Frazer I,
Fridman W,
Gabrilovich D,
Gilboa E,
Gnjatic S,
Jäger D,
Kalinski P,
Kaufman H,
Kiessling R,
Kirkwood J,
Knuth A,
Liblau R,
Lotze M,
Lugli E,
Marincola F,
Melero I,
Melief C,
Mempel T,
Mittendorf E,
Odun K,
Overwijk W,
Palucka A,
Parmiani G,
Ribas A,
Romero P,
Schreiber R,
Schuler G,
Srivastava P,
Tartour E,
Valmori D,
van der Burg S,
van der Bruggen P,
van den Eynde B,
Wang E,
Zou W,
Whiteside T,
Speiser D,
Pardoll D,
Restifo N,
Anderson A.
Consensus nomenclature for CD8(+) T cell phenotypes in cancer. Oncoimmunology 2015 Apr; 4(4):e998538